Page last updated: 2024-10-27

flumazenil and beta-Mannosidase Deficiency

flumazenil has been researched along with beta-Mannosidase Deficiency in 1 studies

Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Safka Brozkova, D1
Varga, L1
Uhrova Meszarosova, A1
Slobodova, Z1
Skopkova, M1
Soltysova, A1
Ficek, A1
Jencik, J1
Lastuvkova, J1
Gasperikova, D1
Seeman, P1

Other Studies

1 other study available for flumazenil and beta-Mannosidase Deficiency

ArticleYear
Variant c.2158-2A>G in MANBA is an important and frequent cause of hereditary hearing loss and beta-mannosidosis among the Czech and Slovak Roma population- evidence for a new ethnic-specific variant.
    Orphanet journal of rare diseases, 2020, 08-26, Volume: 15, Issue:1

    Topics: beta-Mannosidosis; Czech Republic; Deafness; Ethnicity; Hearing Loss; Humans; Minority Groups; Roma;

2020